Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase 1 3

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Accelerated Phase 1Composite Lymphoma 1Breast Neoplasms 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × CT-P10 × Clear all
NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Thomas Jefferson University

Phase 1 Active not recruiting
4 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01729806 2018-04-11

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡